Heterogeneity of treatment response in bronchiectasis clinical trials

Abstract

Improvements in lung function, symptoms and exacerbation frequency are dissociated in bronchiectasis. FEV₁ is poorly responsive and poorly correlated with other key outcome measures. Clinical parameters are poorly predictive of treatment response, suggesting the need to develop biomarkers to identify responders.